• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Hum Vaccin Immunother . Formulation development of a stable influenza recombinant neuraminidase vaccine candidate

tetano

Editor, Senior Moderator
Hum Vaccin Immunother


. 2024 Dec 31;20(1):2304393.
doi: 10.1080/21645515.2024.2304393. Epub 2024 Mar 18. Formulation development of a stable influenza recombinant neuraminidase vaccine candidate

Bing Li[SUP] 1 [/SUP], Irina V Ustyugova[SUP] 2 [/SUP], Lisa Szymkowicz[SUP] 3 [/SUP], Shaolong Zhu[SUP] 3 [/SUP], Marin Ming[SUP] 3 [/SUP], Karen Y Y Fung[SUP] 1 [/SUP], Guadalupe Cortés[SUP] 4 [/SUP], D Andrew James[SUP] 5 [/SUP], Michael Hrynyk[SUP] 6 [/SUP], Nausheen Rahman[SUP] 1 [/SUP], Roger H Brookes[SUP] 1 [/SUP], Salvador F Ausar[SUP] 1 [/SUP]



Affiliations
Abstract

Current influenza vaccines could be augmented by including recombinant neuraminidase (rNA) protein antigen to broaden protective immunity and improve efficacy. Toward this goal, we investigated formulation conditions to optimize rNA physicochemical stability. When rNA in sodium phosphate saline buffer (NaPBS) was frozen and thawed (F/T), the tetrameric structure transitioned from a "closed" to an "open" conformation, negatively impacting functional activity. Hydrogen deuterium exchange experiments identified differences in anchorage binding sites at the base of the open tetramer, offering a structural mechanistic explanation for the change in conformation and decreased functional activity. Change to the open configuration was triggered by the combined stresses of acidic pH and F/T. The desired closed conformation was preserved in a potassium phosphate buffer (KP), minimizing pH drop upon freezing and including 10% sucrose to control F/T stress. Stability was further evaluated in thermal stress studies where changes in conformation were readily detected by ELISA and size exclusion chromatography (SEC). Both tests were suitable indicators of stability and antigenicity and considered potential critical quality attributes (pCQAs). To understand longer-term stability, the pCQA profiles from thermally stressed rNA at 6 months were modeled to predict stability of at least 24-months at 5°C storage. In summary, a desired rNA closed tetramer was maintained by formulation selection and monitoring of pCQAs to produce a stable rNA vaccine candidate. The study highlights the importance of understanding and controlling vaccine protein structural and functional integrity.

Keywords: CQA; Vaccine; antigenicity; conformational stability; freezing/thawing; neuraminidase; recombinant.

 
Back
Top Bottom